+1 862 207 3288 pharmacoeconomic evaluations of infliximab and adalimumab made in NICE TA187
A 1,500 word critical assessment of the pharmacoeconomic evaluations of infliximab and adalimumab made in NICE TA187; http://www.nice.org.uk/nicemedia/live/12985/48552/48552.pdf). You should critically evaluate the economic model used and consider whether or not the conclusions made within the recommendations are supported by the economic evaluation provided. This will require some evaluation of the clinical effectiveness of these agents as reported within the technology appraisal. As part of the critical evaluation you should suggest the feasibility, advantages and disadvantages of alternative pharmacoeconomic models that may have theoretically been applied to this particular technology and indication. This represents 50% of your coursework mark.
Review
This piece of coursework allows you to critically evaluate the pharmacoeconomicmodelling of an active piece of NICE guidance; in this case a technology appraisal for the use of the anti-TNF? drugs infliximab and adalimumab for Crohn’s Disease (TA187). You should consider carefully the assumptions made in the economic modelling and be able, with reference to the clinical effectiveness of the agents in question, to evaluate the utility of the economic arguments used. You should consider in your report other forms of pharmacoeconomic assessment and construct an argument as to the applicability of any alternatives within this context. You should draw a conclusion as to whether or not the findings of the technology appraisal are justified. This piece of work should be appropriately referenced. You may wish to examine the full Crohn’s Disease guidance http://www.nice.org.uk/nicemedia/live/13936/61002/61002.pdf as part of your evaluation; however, it is the specific analysis of the anti-TNF? agents rather than the entirety of management of Crohn’s Disease that is required.
PLACE THIS ORDER OR A SIMILAR ORDER WITH US TODAY AND GET AN AMAZING DISCOUNT 🙂
